Statistical methods leveraging the hierarchical structure of adverse events for signal detection in clinical trials: a scoping review of the methodological literature.

Laetitia de Abreu Nunes, Richard Hooper, Patricia McGettigan, Rachel Phillips
Author Information
  1. Laetitia de Abreu Nunes: Wolfson Institute of Population Health, Queen Mary University of London, London, UK. l.s.deabreununes@qmul.ac.uk.
  2. Richard Hooper: Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
  3. Patricia McGettigan: William Harvey Research Institute, Queen Mary University of London, London, UK.
  4. Rachel Phillips: Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London, UK.

Abstract

BACKGROUND: In randomised controlled trials with efficacy-related primary outcomes, adverse events are collected to monitor potential intervention harms. The analysis of adverse event data is challenging, due to the complex nature of the data and the large number of unprespecified outcomes. This is compounded by a lack of guidance on best analysis approaches, resulting in widespread inadequate practices and the use of overly simplistic methods; leading to sub-optimal exploitation of these rich datasets. To address the complexities of adverse events analysis, statistical methods are proposed that leverage existing structures within the data, for instance by considering groupings of adverse events based on biological or clinical relationships.
METHODS: We conducted a methodological scoping review of the literature to identify all existing methods using structures within the data to detect signals for adverse reactions in a trial. Embase, MEDLINE, Scopus and Web of Science databases were systematically searched. We reviewed the analysis approaches of each method, extracted methodological characteristics and constructed a narrative summary of the findings.
RESULTS: We identified 18 different methods from 14 sources. These were categorised as either Bayesian approaches (n=11), which flagged events based on posterior estimates of treatment effects, or error controlling procedures (n=7), which flagged events based on adjusted p-values while controlling for some type of error rate. We identified 5 defining methodological characteristics: the type of outcomes considered (e.g. binary outcomes), the nature of the data (e.g. summary data), the timing of the analysis (e.g. final analysis), the restrictions on the events considered (e.g. rare events) and the grouping systems used.
CONCLUSIONS: We found a large number of analysis methods that use the group structures of adverse events. Continuous methodological developments in this area highlight the growing awareness that better practices are needed. The use of more adequate analysis methods could help trialists obtain a better picture of the safety-risk profile of an intervention. The results of this review can be used by statisticians to better understand the current methodological landscape and identify suitable methods for data analysis - although further research is needed to determine which methods are best suited and create adequate recommendations.

Keywords

References

  1. Front Immunol. 2022 Jul 07;13:874829 [PMID: 35874673]
  2. Malar J. 2020 Mar 20;19(1):119 [PMID: 32197619]
  3. Stat Methods Med Res. 2004 Jun;13(3):227-38 [PMID: 15198488]
  4. Nat Rev Drug Discov. 2023 Mar;22(3):235-250 [PMID: 36792750]
  5. Biometrics. 2019 Sep;75(3):1000-1008 [PMID: 30690717]
  6. Stat Biopharm Res. 2015 Jul 3;7(3):174-190 [PMID: 26550466]
  7. Biometrics. 2013 Sep;69(3):661-72 [PMID: 23845253]
  8. Pharm Stat. 2014 Jan-Feb;13(1):13-24 [PMID: 23897858]
  9. Stat Med. 2020 May 15;39(10):1541-1557 [PMID: 32050050]
  10. Ann Intern Med. 2018 Oct 2;169(7):467-473 [PMID: 30178033]
  11. J Clin Epidemiol. 2022 Apr;144:185-192 [PMID: 34954021]
  12. Drug Saf. 2022 Sep;45(9):961-970 [PMID: 35840802]
  13. Syst Rev. 2021 Jan 26;10(1):39 [PMID: 33499930]
  14. Ann Intern Med. 2004 Nov 16;141(10):781-8 [PMID: 15545678]
  15. Pharm Stat. 2021 Nov;20(6):1278-1287 [PMID: 34169636]
  16. BMJ Open. 2020 Jun 11;10(6):e036875 [PMID: 32532777]
  17. J Clin Epidemiol. 2020 Nov;127:191-197 [PMID: 32726605]
  18. Stat Med. 2019 Sep 30;38(22):4378-4389 [PMID: 31313376]
  19. Biometrics. 2004 Jun;60(2):418-26 [PMID: 15180667]
  20. BMC Med Res Methodol. 2020 Nov 30;20(1):288 [PMID: 33256641]
  21. J Am Stat Assoc. 2010 Sep 1;105(491):1215-1227 [PMID: 21931466]
  22. J Biopharm Stat. 2013;23(1):213-30 [PMID: 23331232]
  23. Stat Med. 2012 Aug 15;31(18):1918-30 [PMID: 22415725]
  24. Syst Rev. 2016 Dec 5;5(1):210 [PMID: 27919275]
  25. J Biopharm Stat. 2011 Sep;21(5):1006-29 [PMID: 21830928]
  26. J Clin Oncol. 2013 Nov 1;31(31):3957-63 [PMID: 24062406]
  27. Genet Epidemiol. 2013 May;37(4):334-44 [PMID: 23483651]
  28. BMJ Open. 2019 Mar 1;9(2):e024537 [PMID: 30826796]
  29. PLoS One. 2012;7(7):e41174 [PMID: 22911755]
  30. J Biopharm Stat. 2024 Mar;34(2):276-295 [PMID: 37016726]

Grants

  1. 218584/Z/19/Z/Wellcome Trust

MeSH Term

Humans
Bayes Theorem
Data Interpretation, Statistical
Drug-Related Side Effects and Adverse Reactions
Randomized Controlled Trials as Topic
Research Design

Word Cloud

Created with Highcharts 10.0.0methodseventsanalysisadversedatamethodologicaloutcomesreviewegapproachesusestructuresbasedbettertrialsinterventionnaturelargenumberbestpracticesexistingwithinclinicalscopingliteratureidentifysummaryidentifiedBayesianflaggederrorcontrollingtyperateconsideredusedneededadequatedetectionBACKGROUND:randomisedcontrolledefficacy-relatedprimarycollectedmonitorpotentialharmseventchallengingduecomplexunprespecifiedcompoundedlackguidanceresultingwidespreadinadequateoverlysimplisticleadingsub-optimalexploitationrichdatasetsaddresscomplexitiesstatisticalproposedleverageinstanceconsideringgroupingsbiologicalrelationshipsMETHODS:conductedusingdetectsignalsreactionstrialEmbaseMEDLINEScopusWebSciencedatabasessystematicallysearchedreviewedmethodextractedcharacteristicsconstructednarrativefindingsRESULTS:18different14sourcescategorisedeithern=11posteriorestimatestreatmenteffectsproceduresn=7adjustedp-values5definingcharacteristics:binarytimingfinalrestrictionsraregroupingsystemsCONCLUSIONS:foundgroupContinuousdevelopmentsareahighlightgrowingawarenesshelptrialistsobtainpicturesafety-riskprofileresultscanstatisticiansunderstandcurrentlandscapesuitable-althoughresearchdeterminesuitedcreaterecommendationsStatisticalleveraginghierarchicalstructuresignaltrials:ClinicalErrorcontrolFalsediscoveryHarmHierarchicalmodelsMethodologyMultipletestingScopingSignal

Similar Articles

Cited By

No available data.